Search bioRxiv⌕ Search

bioRxiv · 10.1101/2022.11.02.514962

Spinal cord and brain concentrations of riluzole after oral and intrathecal administration: a potential new treatment route for amyotrophic lateral sclerosis

Abstract

Riluzole is the only treatment known to improve survival in patients with Amyotrophic Lateral Sclerosis (ALS). However, oral riluzole efficacy is modest at best, further it is known to have large inter-individual variability of serum concentration and clearance, is formulated as an oral drug in a patient population plagued with dysphagia, and has known systemic side-effects like asthenia (limiting patient compliance) and elevated liver enzymes. In this context, we postulated that continuous intrathecal (IT) infusion of low doses of riluzole could provide consistent elevations of the drug spinal cord (SC) concentrations at or above those achieved with oral dosing, without increasing the risk for adverse events associated with systemic drug exposure or off-target side effects in the brain. We developed a formulation of riluzole for IT delivery and conducted our studies in purpose-bred hound dogs. Our non-GLP studies revealed that IT infusion alone was able to increase SC concentrations above those provided by oral administration, without increasing plasma concentrations. We then conducted two GLP studies that combined IT infusion with oral administration at human equivalent dose, to evaluate SC and brain concentrations of riluzole along with assessments of safety and tolerability. In the 6-week study, the highest IT dose (0.2 mg/hr) was well tolerated by the animals and increased SC concentrations above those achieved with oral riluzole alone, without increasing brain concentrations. In the 6-month study, the highest dose tested (0.4 mg/hr) was not tolerated and yielded SC significantly above those achieved in all previous studies. Our data show the feasibility and safety profile of continuous IT riluzole delivery to the spinal cord, without concurrent elevated liver enzymes, and minimal brain concentrations creating another potential therapeutic route of delivery to be used in isolation or in combination with other therapeutics."

Source connections

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Keifer, O., Gutierrez Gonzalez, J., Butt, M., Cramer, S., Bartus, R., Tansey, M., Deaver, D., Betourne, A., Boulis, N.. 2022-11-03. Spinal cord and brain concentrations of riluzole after oral and intrathecal administration: a potential new treatment route for amyotrophic lateral sclerosis. https://doi.org/10.1101/2022.11.02.514962

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

E2F4 gene therapy reverses established synaptic and cognitive deficits and remodels learning-associated signaling in Alzheimer's disease mice

Alzheimer's disease (AD) causes progressive synaptic dysfunction, neurodegeneration, and cognitive decline, yet strategies capable of reversing established deficits remain limited. Here, we show that neuronal expression of a p38MAPK phosphorylation-resistant human E2F4 variant (hE2F4DN), delivered by adeno-associated virus, restores hippocampal long-term potentiation and memory in homozygous 5xFAD mice after functional impairment is established. Treatment also reduces amyloid-{beta} and phospho-tau pathology and prevents hippocampal neuronal loss. Integrated proteomic and phosphoproteomic analyses reveal remodeling of metabolic, redox, neuroimmune, synaptic-vesicle, and GSK3{beta}-associated signaling pathways. Following contextual fear conditioning, hE2F4DN-treated mice exhibit broader learning-associated synaptic proteomic signatures and distinct phosphoregulatory responses involving synaptic machinery. These findings demonstrate that E2F4 gene therapy can reverse established synaptic and cognitive deficits while preserving neuronal integrity and reshaping molecular responses to learning, identifying E2F4 phosphorylation as a potential therapeutic target for advanced AD states.

neuroscience↗

Complex Spatial and Temporal Organization of Functional Brain Networks

Recent research exploring brain-behavior associations has relied on the language of complex systems to understand how stable behavioral individual differences emerge from brain function. At the same time, advances in neuroimaging have provided greater insight into both the topological and temporal properties of macroscale cortical networks. These new approaches offer a potential avenue for understanding how functional activity in the brain might behave in a manner that aligns with complex-systems interpretations of psychological traits. The present study used resting-state data from the Human Connectome project (N = 994) to explore associations between the spatial and temporal features of functional brain networks. Using an adaptive frequency approach to explore brain function at different timescales together with a family of methods from complex systems theory, we identified patterns of brain state organization reflecting a state-trait continuum, with more stable trait-like dynamics and greater functional coupling between networks in lower frequency oscillations. Additionally, we found evidence of greater coupling across timescales in brain networks associated with higher-order cognition. This research supports interpretations of brain organization as a spatiotemporal hierarchy and provides future avenues for exploring brain-behavior associations from a complex system perspective.

neuroscience↗

A Mechanistic Account of Dedifferentiation in the Aging Visual System

To uncover the mechanisms of age-related dedifferentiation, we simulated neural degradation in a computational model of the ventral visual stream. Severing connections or adding noise, whether in inferotemporal cortex (IT) or upstream, reduced IT differentiation, indicating that dedifferentiation need not originate locally. Degrading peripheral V1, which preferentially drove place-selective IT neurons, selectively reduced place differentiation, a candidate mechanism for the stronger place dedifferentiation reported in aging.

neuroscience↗